British Patient Capital has participated in the USD60 million Series B funding round of Paragraf, a Cambridge-based graphene-based electronics company.
This investment is being made through British Patient Capital’s Future Fund: Breakthrough programme, a GBP375 million initiative where British Patient Capital co-invests alongside private sector investors in later stage R&D-intensive UK companies.
Paragraf develops and delivers game-changing, commercial-quality, graphene-based electronic devices using contamination-free technology that is both scalable and compatible with existing electronic device manufacturing production processes.